Institute receives Platinum Green Impact Award for 2020/21
The Cancer Research UK Cambridge Institute has achieved Platinum in the University’s Green Impact Awards.
Green Impact is the University of Cambridge’s environmental accreditation scheme. It supports and encourages departments and colleges across the University in reducing their environmental impacts.
With support from the Environment and Energy Section, departments can form a small team, who sign up to an online workbook and progress through simple, clear and easy criteria towards recognised awards and targets.
Over the last year, our Green Impact team has been working hard to implement new green initiatives within the building, including green procurement agreements, supporting biodiversity onsite, introducing new recycling systems, and creating a pledge programme for staff. Many thanks to the team members: Grace Davison, Cathy Pauley, Emma Wright, Chloe Cashman, Amy Cullen, Beverly Bernhardt, Allan Lui and Colin Weir.
The auditor said “The team has done excellent work in embedding sustainability across the department. The actions taken were well planned and clearly communicated, with evidence of enthusiastic participation from the department. Well done everyone!”
The Institute continues to be fully committed to reducing our impact on the environment wherever possible.
Related News
See all news-
Dr Guiping Wang appointed as a Junior Group Leader
18th May 2026
Dr Guiping Wang joins the Cancer Research UK Cambridge Institute as a Junior Group Leader, starting in September 2026.
Find out more -
Shankar Balasubramanian receives the Princess of Asturias Award for Scientific and Technical Research
14th May 2026
The 2026 award recognises Prof Balasubramanian and his co-recipients David Klenerman and Pascal Meyer for their pioneering work in genome sequencing technologies.
Find out more -
Prof Sir Steve Jackson receives the 2026 Galen Medal in Therapeutics
14th May 2026
This award comes in recognition of his transformational work on the mechanisms of DNA repair, cell survival and the DNA-damage response (DDR), as well as for the development of the cancer-targeting drug Olaparib.
Find out more